Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 1 - Drugs for disorders of the alimentary tract or the digestive system
Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798)
12/1999
12/02/1999CA2332786A1 Identification of broadly reactive dr restricted epitopes
12/02/1999CA2332459A1 Heterocyclic compounds and methods to treat cardiac failure and other disorders
12/02/1999CA2332402A1 Novel 2-alkyl substituted imidazole compounds
12/02/1999CA2329072A1 Human transmembrane proteins
12/02/1999CA2328451A1 Differential cytotoxicity of alternative forms of rotavirus nonstructural protein 4
12/02/1999CA2327541A1 Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using serine proteases
12/02/1999CA2321927A1 Treatment of c. difficile toxin b associated conditions
12/01/1999EP0960883A1 Substituted thiazolidinedione derivatives
12/01/1999EP0960118A1 Nucleotide and protein sequences of liver activin/inhibin and methods based thereon
12/01/1999EP0960098A1 Arylsulfonyl hydroxamic acid derivatives
12/01/1999EP0959892A1 Use of pvp or povidone for reducing bowel distension
12/01/1999EP0959872A1 Methods, compositions, and dental delivery systems for the protection of the surfaces of teeth
12/01/1999EP0582631B1 Use of S-nitrosothiols for the preparation of a medicament for the relaxation of smooth muscle
12/01/1999CN1237179A 1,2,3,4-tetrahydro-benzofuro [3,2-c] pyridine derivatives
12/01/1999CN1237168A Bicyclic aryl carboxamides and their therapeutic use
12/01/1999CN1237159A Pure enantiomer basic aryl-cycloalkyl-hydroxycarboxylic acid esters, process for preparing same and their use in medicaments
12/01/1999CN1237105A Reflux inhibitors
12/01/1999CN1236639A Chinese patent medicine for treating chronic gastritis and peptic ulcer
12/01/1999CN1236632A Medicinal composition for treating recurrent aphthae
11/1999
11/30/1999USRE36419 Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
11/30/1999US5994517 Homogeneous conjugate of carbohydrate ligand which binds to hepatic receptor, a bifunctional linker, and a biological stable oligonucleotide and derivative can be released from conjugate; for targeted antisense agents
11/30/1999US5994500 Antagonists of intestinotrophic GLP-2 peptides
11/30/1999US5994391 Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
11/30/1999US5994379 Analgesics; antiinflammatory agent; antipyretics
11/30/1999US5994372 Peripherally active anti-hyperalgesic opiates
11/30/1999US5994369 Substituted piperidine or pyrrolidine compounds for treating sigma-receptor modulated disorders
11/30/1999US5994350 Cardiovascular disorders; central nervous system disorders; gastrointestinal disorders; respiratory system disorders
11/30/1999US5994344 Bronchitis therapy
11/30/1999US5994312 Peptidyl compounds
11/30/1999US5994293 Peptidyl compounds and their therapeutic use
11/30/1999US5994111 A polypeptide; treatment and diagnosis of respiratory infections, septic arthritis, cardiovascular infections, gastrointestinal infections, toxic shock syndrome; antibiotics
11/30/1999US5994100 HAS2 splicing variant HOEFC11: a target in chronic renal failure, inflammatory diseases and myocardial ischemia
11/30/1999US5994098 G protein coupled receptor gene; treatment of pain, diabetes, eating disorders, asthma; hypotensive/hypertensive agents; parkinson's/huntington's/cardiovascular diseases, ulcers, anticarcinogenic/antiallergens agents; osteoprosis,
11/30/1999US5994096 Regulator
11/30/1999US5994094 A bone morphogenetic protein; treatment of osteoporosis, prevent transplant rejection; wound healing agents; regeneration of bones, cartilage, connective tissue, skin, mucous membranes, epithelium and teeth
11/30/1999US5993845 Histone deacetylase inhibitor and a pharmaceutically acceptable carrier wherein the composition comprises from 0.05 to 100 mg of the histone deacetylase inhibitor.
11/30/1999US5993785 Mouthwash compositions
11/30/1999CA2179011C 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
11/25/1999WO1999060132A1 Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
11/25/1999WO1999060015A1 Imidazolidine derivatives, the production thereof, their use and pharmaceutical preparations containing the same
11/25/1999WO1999060012A1 Compositions and methods for non-parenteral delivery of oligonucleotides
11/25/1999WO1999059975A1 Fused tricyclic compounds which inhibit parp activity
11/25/1999WO1999059973A1 Carboxamide compounds, compositions, and methods for inhibiting parp activity
11/25/1999WO1999059959A1 Benzamide derivatives for the treatment of diseases mediated by cytokines
11/25/1999WO1999059621A1 Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection
11/25/1999WO1999059612A1 Method for the treatment of gastroesophageal reflux disease
11/25/1999WO1999059606A1 Use of rosmarinic acid and derivatives thereof as an immunosuppressant or an inhibitor of sh2-mediated process
11/25/1999WO1999059587A1 Anti-viral compounds
11/25/1999WO1999059576A1 Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
11/25/1999WO1999059570A1 Protease inhibitors
11/25/1999WO1999059553A1 Effervescent preparations
11/25/1999WO1999059549A1 Biodegradable sustained-release alginate gels
11/25/1999WO1999059544A2 Orally disintegrable tablets
11/25/1999WO1999059526A2 Protease inhibitors
11/25/1999WO1999044595A3 Pharmaceutical compositions for ulcer
11/25/1999CA2587022A1 Orally disintegrable tablets
11/25/1999CA2332774A1 Method for the treatment of gastroesophageal reflux disease
11/25/1999CA2332531A1 Protease inhibitors
11/25/1999CA2332492A1 Protease inhibitors
11/25/1999CA2332462A1 Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
11/25/1999CA2332403A1 Anti-viral compounds
11/25/1999CA2332279A1 Carboxamide compounds, compositions, and methods for inhibiting parp activity
11/25/1999CA2332239A1 Fused tricyclic compounds which inhibit parp activity
11/25/1999CA2331875A1 Imidazolidine derivatives, the production thereof, their use and pharmaceutical preparations containing the same
11/25/1999CA2331823A1 Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection
11/25/1999CA2329130A1 Compositions and methods for non-parenteral delivery of oligonucleotides
11/24/1999EP0958282A1 2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines
11/24/1999EP0958277A1 Nitric oxide synthase inhibitors
11/24/1999EP0957907A1 Il-8 receptor antagonists
11/24/1999EP0957904A2 Compositions comprising choline and use of choline to treat endotoxic shock
11/24/1999EP0957901A1 Pharmaceutical preparations of glutathione and methods of administration thereof
11/24/1999EP0957806A1 COMPOSITIONS TO CONTROL ORAL MICROBIAL OXIDATION-REDUCTION (E h?) LEVELS
11/24/1999EP0730470A4 Improved interferon polymer conjugates
11/24/1999EP0550703B1 Plant-based medicament for enhancing and controlling the tone of smooth-muscle organs
11/24/1999CN1236319A Pharmaceutical composition containing a mixed extract of phellodondron amurense amurense ruprecht cortex and patrinia scabiosaefolia fish for treatment of hepatitis C
11/24/1999CN1235967A Carbazolone derivatives
11/24/1999CN1235845A Health care liquid and its preparing method
11/24/1999CN1235824A Process for producing enteric coated pancreatin granules
11/24/1999CN1046726C Imidazopyridine-pyrrolidone, its preparation and medical use
11/24/1999CN1046724C Pyrazolopyridine compounds, pharmaceutical containing them, and its preparing method and use
11/24/1999CN1046723C Tetracyclic compounds, pharmaceutical containing them and its use
11/24/1999CN1046718C 6-(2-imidzolinylamino) quinoline compounds useful as alpha-2-adrenoceptor agonists
11/23/1999US5990314 Pharmaceutical pyridine compounds
11/23/1999US5990159 Pharmaceutical formulations comprising a selective serotonin reuptake inhibitors and a 5ht4 receptor antagonists; reduction of gastrointestinal side effects
11/23/1999US5990148 Side effect reductions; antiarthritic agents; nonsteroidal antiinflammatory agents
11/23/1999US5990109 Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
11/23/1999US5990108 5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one derivatives, preparation thereof, intermediates thereof and drugs containing the same
11/23/1999US5990103 Treating psoriasis by topical adminstration of pentoxifylline and diltiazem to a patient; a combination of a compound having a phosphodiesterase-inhibiting action, and a compound which reduces the intracellular calcium content
11/23/1999US5990077 Glp-2 acts as a trophic agent to promote growth of gastrointestinal tissue, particularly increased growth of the small intestine and pancreatic islet; pharmaceutical compositions; treating diabetes
11/23/1999US5989907 Methods and compositions for calcium binding proteolipid encoding nucleic acids
11/23/1999US5989858 Dead-type ATP-dependent RNA helicase (DbpB) from Staphylococcus aureus
11/23/1999US5989834 Contacting nonneuronal cells transfected with vector; gene expression
11/23/1999US5989803 Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase
11/23/1999US5989584 CCK antibodies used to improve feed efficiency
11/23/1999US5989560 Herbal intestinal tract cleanser
11/23/1999US5989544 Injesting alpha-galactosidase to hydrolyze galactosides
11/23/1999CA2006184C Prolonged release composition based on trimebutine and process for the preparation thereof
11/18/1999WO1999058642A2 Secreted proteins and polynucleotides encoding them
11/18/1999WO1999058573A1 Diagnosis and treatment of hepatic disorders
11/18/1999WO1999058555A2 Water-soluble pro-drugs of 2,6-diisopropylphenol analogues
1 ... 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 ... 1258